Dec 3 (Reuters) - Japan's Kaneka Corp 4118.T has entered
into a deal to manufacture Inovio Pharmaceuticals Inc's INO.O
COVID-19 vaccine candidate, the U.S.-based vaccine maker said on
Thursday.
It did not disclose the terms of the agreement with Kaneka
Eurogentec, a unit of the Japanese chemical company.
Inovio has also signed manufacturing deals with medical
device maker Thermo Fisher Scientific TMO.N among others, to
increase supply of the vaccine, which entered a mid-stage study
last month.
The Phase 3 of the mid-to-late stage study is under a
partial hold by the U.S. Food and Drug Administration as it
seeks more information, including details on a delivery device
used to inject genetic material into cells.
(Reporting by Amruta Khandekar; Editing by Shinjini Ganguli)
((Amruta.Khandekar@thomsonreuters.com;))